Epidermal growth factor receptor tyrosine kinase inhibitors in combination with HGF-receptor inhibitors for treatment of cancer
Identification by using a defined MET amplification and/or overexpression assay cutoff value in NSCLC patients and combined with a combination of EGFR TKI with c-MET inhibitors resolves the development of MET-driven resistance after previous treatment with EGFR TKI, significantly improving treatment efficacy and patient survival.
Patent Information
- Application Number
- CN202380057880.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-05
- Filing Date
- 2023-07-07
- Publication Date
- 2025-03-18
AI Technical Summary
The prior art is difficult to effectively identify and treat NSCLC in patients developing MET-driven resistant after previous treatment with EGFR TKI.
Patients with EGFRm+ NSCLC are identified by determining cutoff values using defined MET amplification and/or overexpression and EGFR TKI is used in combination with c-MET inhibitors, especially if the patient's cancer has high or very high levels of MET amplification and/or overexpression.
Accurate identification of patients who are most likely to benefit from the combination of MET TKI and EGFR TKI therapy was achieved, prolonging progression-free survival, improving objective response rates, and significantly improving the therapeutic effect of NSCLC patients who progressed after osimertinib treatment.